Anti-Human GPC2/Glypican-2 Antibody (D3), APC

Catalog No.

FHK80623

Species reactivity

Human

Host species

Mouse

Isotype

IgG2a, kappa

Clonality

Monoclonal

Conjugation

APC

Target

Glypican-2, GPC2

Concentration

0.5 mg/ml

Endotoxin level

Please contact with the lab for this information.

Accession

Q8N158

Applications

FCM

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4, 0.2% BSA, 0.05% Proclin 300.

Stability and Storage

Store at 4°C for 12 months. Protect from light. Do not freeze.

Clone ID

D3

Structural Features of Glypicans and their Impact on Wnt Signaling in Cancer., PMID:40416340

rhIL-7-hyFc, a long-acting interleukin-7, improves efficacy of CAR-T cell therapy in solid tumors., PMID:39043602

Enhanced anti-tumor activity mediated by combination chimeric antigen receptor T cells targeting GD2 and GPC2 in high-risk neuroblastoma., PMID:38904586

Attenuation of cancer proliferation by suppression of glypican-1 and its pleiotropic effects in neoplastic behavior., PMID:36944188

GPC2 antibody-drug conjugate reprograms the neuroblastoma immune milieu to enhance macrophage-driven therapies., PMID:36460335

Development of GPC2-directed chimeric antigen receptors using mRNA for pediatric brain tumors., PMID:36167467

Development of Glypican-2 Targeting Single-Domain Antibody CAR T Cells for Neuroblastoma., PMID:35157288

Antibody-Drug Conjugate Efficacy in Neuroblastoma: Role of Payload, Resistance Mechanisms, Target Density, and Antibody Internalization., PMID:34465595

A GPC2 antibody-drug conjugate is efficacious against neuroblastoma and small-cell lung cancer via binding a conformational epitope., PMID:34337560

CAR T cells targeting tumor-associated exons of glypican 2 regress neuroblastoma in mice., PMID:34195677

Advances in immunotherapeutic targets for childhood cancers: A focus on glypican-2 and B7-H3., PMID:33992682

Glypicans as Cancer Therapeutic Targets., PMID:30352677

Identification of GPC2 as an Oncoprotein and Candidate Immunotherapeutic Target in High-Risk Neuroblastoma., PMID:28898695

Scratching the Surface of Immunotherapeutic Targets in Neuroblastoma., PMID:28898689

Therapeutically targeting glypican-2 via single-domain antibody-based chimeric antigen receptors and immunotoxins in neuroblastoma., PMID:28739923

Identification of cell surface proteins as potential immunotherapy targets in 12 pediatric cancers., PMID:23251904

Glypican-2 binds to midkine: the role of glypican-2 in neuronal cell adhesion and neurite outgrowth., PMID:12084985

Cerebroglycan, a developmentally regulated cell-surface heparan sulfate proteoglycan, is expressed on developing axons and growth cones., PMID:9133438

The maize cytosolic glyceraldehyde-3-phosphate dehydrogenase gene family: organ-specific expression and genetic analysis., PMID:1717817

Document Download

Anti-Human GPC2/Glypican-2 Antibody (D3), APC.pdf